Wockhardt Q1 FY27 Results Analysis: EBITDA Margin Expands 1091 bps, PAT Swings to Profit (WOCKPHARMA)

Wockhardt Ltd reported Q1 FY27 numbers. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Wockhardt reported a strong operational turnaround with consolidated revenue up 25.88% YoY and EBITDA margin expanding 1091 bps to 20.67%. The company achieved a clean PAT of Rs.107 Cr versus a loss last year, aided by the completed US generics exit and strong domestic growth. Key catalysts include the Zaynich FDA approval and credit rating upgrade, though near-term margins may be impacted by launch costs.

Key Investment Insights

Key Positives

• Consolidated revenue grew 25.88% YoY to Rs.929 Cr.
• Consolidated EBITDA margin expanded from 9.76% to 20.67% YoY.
• PAT swung from a loss of Rs.108 Cr to a profit of Rs.107 Cr.
• Standalone revenue surged 35.84% YoY to Rs.561 Cr.
• ICRA upgraded long-term rating to A- (Stable) from BBB (Positive).
• U.S. FDA approval for Zaynich (cUTI) received.
• Subsidiaries turned from a Rs.159 Cr PAT drag to a negligible Rs.1 Cr drag.

Risk Factors

• Consolidated EBITDA margin contracted QoQ from 23.32% to 20.67%, partly due to normal seasonality and Zaynich pre-launch cost build.
• Standalone EBITDA margin declined slightly YoY from 31.72% to 28.16%.
• Other income contributed 29% of PAT (Rs.31 Cr out of Rs.107 Cr), indicating reliance on non-operating income.
• Inventory build of Rs.22 Cr boosted P&L, a timing effect under Ind AS 2.